comparemela.com
Home
Live Updates
Zentalis Pharmaceuticals : Regains Worldwide Development and Commercialization Rights to Azenosertib, ZN-d5 and ZN-c5 As a Result of Termination of Greater China Collaboration and License Agreements - Form 8-K : comparemela.com
Zentalis Pharmaceuticals : Regains Worldwide Development and Commercialization Rights to Azenosertib, ZN-d5 and ZN-c5 As a Result of Termination of Greater China Collaboration and License Agreements - Form 8-K
zntl-20230615
UNITED STATES
... | June 15, 2023
Related Keywords
Washington ,
United States ,
Taiwan ,
Delaware ,
New York ,
Macau ,
China ,
Hong Kong ,
Republic Of China ,
Taiwan General ,
Melissa Epperly ,
Securities Exchange ,
Zentalis Pharmaceuticals Inc ,
Zentalis Regains Worldwide Development ,
Securities Exchange Act ,
Zip Code ,
Securities Act ,
Exchange Act ,
Regains Worldwide Development ,
Commercialization Rights ,
Greater China Collaboration ,
Zentalis Pharmaceuticals ,
License Agreements ,
Zentera Therapeutics ,
Greater China ,
comparemela.com © 2020. All Rights Reserved.